Exploration of the Lipid Metabolism During the Diabetic Pregnancies

Summary

Justification:

Intrauterine exposure to type 1 or type 2 diabetes increase the risk of macrosomia (35 % to 50 % versus 10 % in general population) despite a good glycemic control. The consequences are : shoulder's dystocia, lung immaturity, caesarean section, neonatal hypoglycaemia and a high frequency of obesity and metabolic disorders in adults.

The mechanisms of macrosomia are unclear; chronic hyperglycemia and subsequent hyperinsulinaemia observed during the diabetic pregnancy might explain only partially the fetal weight. Considerable interest has been generated over the last decade on the lipids and fatty acids alterations in diabetes pregnancies. Change in lipoproteins metabolism have been described associated with macrosomia. Maternal nutrition before and during pregnancy plays an important role in fetal growth and subsequent development of an increased susceptibility to obesity and diabetes in later life.

Main objective:

Looking for an association between maternal and fetal blood lipid parameters and birth weight and body fat in a context of type 1 or type 2 diabetes.

Secondary objectives:

* Identify lipid markers associated with fetal macrosomia.
* Analyze the placenta by measuring the expression of genes implicated in the storage and the transfer of fatty acids.
* Analyze and compare the expression level of placental genes subjected to parental imprinting and validated in animal models.

Conditions

• Pregnancy
• Pregnancy in Diabetes
• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

Interventions

OTHER

blood tests

3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord

OTHER

diet questionnaire

questions about nutrition before and during pregnancy

OTHER

umbilical cord blood collect

collected at the delivery

OTHER

placenta collect

collected at the delivery

Sponsors & Collaborators

• Ministry of Health, France

  collaborator OTHER_GOV

• University Hospital, Lille

  lead OTHER

Principal Investigators

• Anne VAMBERGUE, MDPHD · University Hospital, Lille

• Isabelle FAJARDY, PharmD · Univesity Hospital, Lille

• Annie MARTIN, PharmD PhD · University Hospital, Lille

• Gilbert BRIAND, PhD · University Hospital, Lille

• Jean ROUSSEAUX, MDPhD · University Hospital, Lille

• Damien SUBTIL, MD · University Hospital, Lille

• Philippe DUFOUR, MD · University Hospital, Lille

• Pierre FONTAINE, MDPHD · University Hospital, Lille

• Philippe DERUELLE, MD · University Hospital, Lille

• Salha FENDRI, MD · Amiens University Hospital

• Françoise LE GOUEFF, MD · Centre Hospitalier de Roubaix

• Delphine VINCENT-DESPLANQUE, MD · Centre Hospitalier de Roubaix

• Lucie BRESSON, MD · Lille University Hospital

• Eleonore DELARUE, MD · University Hospital of Lille

• Odile GAGNEUR, MD · University Hospital of Lille

Study Design

Allocation

NON_RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2008-01-31

Primary Completion

2012-01-31

Completion

2013-12-31

Countries

• France

Study Locations